The company's lead candidate, REX-001, is an autologous cell therapy that is being studied in a Phase III clinical program in patients with critical limb ischemia with diabetes.

Rexgenero, which was founded in Spain but is now based in the UK, is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.